Heartflow Revolutionizes Cardiovascular Care with Landmark 8,000 Patient Study
Introduction to Heartflow’s Groundbreaking Study
In a pioneering development within the realm of cardiovascular medicine, Heartflow, Inc. (Nasdaq: HTFL), a leader in AI technology for managing coronary artery disease (CAD), has unveiled remarkable results from the largest-ever analysis of its Heartflow Plaque Staging framework. These findings were revealed during the highly anticipated American Heart Association (AHA) Scientific Sessions 2025.
FISH&CHIPS Study: A Deeper Dive
The FISH&CHIPS study, a multicenter collaborative effort, delved into the data from nearly 8,000 symptomatic patients. The primary focus was to validate the role of total plaque volume (TPV) as an independent predictor of long-term cardiovascular events. As stated in Stock Titan, patients occupying the highest TPV stage face a staggering 5.10 times greater risk of major cardiovascular events than those in the lowest stage.
Key Findings: The Impact of TPV
The retrospective analysis presented in New Orleans highlights several critical findings. A strong correlation between high plaque volume stages and increased cardiovascular death rates and myocardial infarctions was noted. These insights were robust, surviving adjustments for common cardiovascular risk factors.
Dr. Timothy Fairbairn, the principal investigator for the study, emphasized, “By accurately measuring plaque, cardiologists are now better equipped to predict and personalize patient care, surmounting traditional risk assessment methods.”
Insights from the DECIDE Registry
Building on previous research, the DECIDE Registry presented earlier this year, showcased Heartflow’s profound impact. Over half of the participating patients witnessed substantial changes in their medical management, thanks to Heartflow’s AI-driven plaque analysis. This shift reduced LDL cholesterol by an average of 18.7 mg/dL within 90 days, consequently lowering cardiac event risk by an expected 15%.
Transforming Cardiac Patient Management
Dr. Campbell Rogers, Heartflow’s Chief Medical Officer, exclaimed, “The findings underscore how embedding plaque insights into the diagnostic path rewires the management of CAD, empowering physicians with precision and confidence.”
About Heartflow’s Cutting-edge Technology
The story behind Heartflow’s technology is equally compelling. With an unmatched coronary imaging dataset, bolstered by ACC/AHA guidelines and endorsed by extensive peer-reviewed research, Heartflow is at the vanguard of redefining cardiovascular care globally.
With Heartflow’s innovative AI solutions already touching the lives of nearly 500,000 patients, this technology promises a future where precision cardiovascular care is within everyone’s reach, transforming the way we understand and treat heart disease.
